Wall Street analysts forecast that Accuray Incorporated (NASDAQ:ARAY) will post earnings of ($0.03) per share for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Accuray’s earnings. The lowest EPS estimate is ($0.04) and the highest is ($0.02). Accuray posted earnings of ($0.06) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 50%. The business is expected to issue its next quarterly earnings report on Thursday, April 26th.
According to Zacks, analysts expect that Accuray will report full-year earnings of ($0.19) per share for the current year, with EPS estimates ranging from ($0.25) to ($0.14). For the next financial year, analysts expect that the business will report earnings of ($0.05) per share, with EPS estimates ranging from ($0.09) to ($0.03). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that cover Accuray.
Accuray (NASDAQ:ARAY) last posted its earnings results on Tuesday, January 23rd. The medical equipment provider reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.05. Accuray had a negative return on equity of 44.66% and a negative net margin of 6.09%. The company had revenue of $100.33 million for the quarter, compared to analyst estimates of $90.31 million. During the same quarter last year, the company earned ($0.11) earnings per share. The company’s revenue for the quarter was up 14.7% on a year-over-year basis.
Several institutional investors and hedge funds have recently modified their holdings of the stock. MetLife Investment Advisors LLC purchased a new stake in shares of Accuray during the fourth quarter valued at approximately $160,000. Two Sigma Investments LP increased its position in Accuray by 189.5% in the fourth quarter. Two Sigma Investments LP now owns 404,736 shares of the medical equipment provider’s stock worth $1,740,000 after buying an additional 264,941 shares during the last quarter. Two Sigma Advisers LP increased its position in Accuray by 15.4% in the fourth quarter. Two Sigma Advisers LP now owns 148,930 shares of the medical equipment provider’s stock worth $640,000 after buying an additional 19,900 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Accuray by 22.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 126,726 shares of the medical equipment provider’s stock worth $545,000 after buying an additional 23,189 shares during the last quarter. Finally, Deutsche Bank AG increased its position in Accuray by 142.0% in the fourth quarter. Deutsche Bank AG now owns 181,513 shares of the medical equipment provider’s stock worth $778,000 after buying an additional 106,501 shares during the last quarter. 82.01% of the stock is owned by institutional investors.
Accuray (NASDAQ ARAY) traded down $0.08 during mid-day trading on Wednesday, hitting $5.62. The stock had a trading volume of 123,313 shares, compared to its average volume of 1,006,347. Accuray has a 52 week low of $3.60 and a 52 week high of $6.15. The company has a quick ratio of 0.99, a current ratio of 1.54 and a debt-to-equity ratio of 2.66. The company has a market capitalization of $481.91, a price-to-earnings ratio of -19.31 and a beta of 1.71.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.